FourThought Financial Partners LLC Grows Stake in Insulet Corporation $PODD

FourThought Financial Partners LLC lifted its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 9.2% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6,678 shares of the medical instruments supplier’s stock after acquiring an additional 563 shares during the period. FourThought Financial Partners LLC’s holdings in Insulet were worth $2,098,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. Cetera Investment Advisers raised its holdings in Insulet by 167.0% during the first quarter. Cetera Investment Advisers now owns 6,455 shares of the medical instruments supplier’s stock worth $1,695,000 after purchasing an additional 4,037 shares in the last quarter. Mediolanum International Funds Ltd grew its position in shares of Insulet by 139.2% in the 1st quarter. Mediolanum International Funds Ltd now owns 21,264 shares of the medical instruments supplier’s stock valued at $5,502,000 after buying an additional 12,374 shares during the last quarter. HB Wealth Management LLC raised its stake in Insulet by 48.9% during the 1st quarter. HB Wealth Management LLC now owns 2,280 shares of the medical instruments supplier’s stock worth $599,000 after acquiring an additional 749 shares in the last quarter. Empirical Finance LLC lifted its position in Insulet by 8.9% in the first quarter. Empirical Finance LLC now owns 1,149 shares of the medical instruments supplier’s stock valued at $302,000 after acquiring an additional 94 shares during the last quarter. Finally, Mackenzie Financial Corp lifted its position in Insulet by 39.9% in the first quarter. Mackenzie Financial Corp now owns 10,576 shares of the medical instruments supplier’s stock valued at $2,777,000 after acquiring an additional 3,015 shares during the last quarter.

Insider Buying and Selling

In other news, SVP Prem Singh sold 687 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the sale, the senior vice president directly owned 3,456 shares of the company’s stock, valued at $1,200,925.44. This trade represents a 16.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.39% of the stock is currently owned by insiders.

Insulet Stock Performance

Shares of PODD opened at $337.53 on Tuesday. The stock has a market capitalization of $23.74 billion, a P/E ratio of 102.59, a P/E/G ratio of 2.64 and a beta of 1.39. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. Insulet Corporation has a 1 year low of $230.05 and a 1 year high of $354.88. The company’s fifty day moving average is $322.16 and its two-hundred day moving average is $316.00.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.11. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business had revenue of $521.70 million for the quarter, compared to the consensus estimate of $678.70 million. During the same quarter in the previous year, the firm earned $1.08 earnings per share. The business’s quarterly revenue was up 29.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, sell-side analysts predict that Insulet Corporation will post 3.92 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Insulet in a report on Wednesday, October 8th. Morgan Stanley restated an “overweight” rating on shares of Insulet in a research note on Thursday, August 7th. Wall Street Zen raised Insulet from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Stifel Nicolaus began coverage on Insulet in a research note on Tuesday, October 21st. They issued a “buy” rating and a $370.00 price objective for the company. Finally, Jefferies Financial Group raised their target price on shares of Insulet from $375.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $379.65.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.